I期临床-话题@MedSci

#I期临床#

570篇内容 | 7029人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1652824, encodeId=e6b91652824c3, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=AsiDNA 治疗晚期实体瘤的I期临床试验正式启动, objectType=article, longId=136480, objectId=e597136480eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e597136480eb, replyNumber=0, likeNumber=80, createdTime=2018-12-07, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e597136480eb, moduleTitle=AsiDNA 治疗晚期实体瘤的I期临床试验正式启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e597136480eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652842, encodeId=19841652842df, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Theravance生物制药宣布TD-8236进入I期临床试验, objectType=article, longId=154603, objectId=73d3154603fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73d3154603fa, replyNumber=0, likeNumber=80, createdTime=2019-06-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73d3154603fa, moduleTitle=Theravance生物制药宣布TD-8236进入I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73d3154603fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652834, encodeId=397816528342f, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据, objectType=article, longId=146735, objectId=31ee146e35d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31ee146e35d9, replyNumber=0, likeNumber=98, createdTime=2019-03-31, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31ee146e35d9, moduleTitle=柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31ee146e35d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652804, encodeId=34b2165280437, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, objectType=article, longId=122745, objectId=1ede122e4567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1ede122e4567, replyNumber=0, likeNumber=26, createdTime=2018-05-04, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1ede122e4567, moduleTitle=【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1ede122e4567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652822, encodeId=4ec41652822bf, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Clin Oncol：II期临床显示Crizotinib在东亚患者中具有抗肿瘤活性, objectType=article, longId=133918, objectId=05b213391822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05b213391822, replyNumber=0, likeNumber=56, createdTime=2018-09-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05b213391822, moduleTitle=J Clin Oncol：II期临床显示Crizotinib在东亚患者中具有抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05b213391822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652832, encodeId=df14165283277, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=III期临床TOLEDO研究显示阿扑吗啡可有效缓解帕金森病（PD）患者的持续运动波动, objectType=article, longId=145966, objectId=6cc314596637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cc314596637, replyNumber=0, likeNumber=51, createdTime=2019-03-20, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cc314596637, moduleTitle=III期临床TOLEDO研究显示阿扑吗啡可有效缓解帕金森病（PD）患者的持续运动波动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cc314596637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652835, encodeId=d93c165283545, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功, objectType=article, longId=146747, objectId=d9eb146e4766, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9eb146e4766, replyNumber=0, likeNumber=82, createdTime=2018-10-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9eb146e4766, moduleTitle=每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9eb146e4766)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652805, encodeId=16171652805ab, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著, objectType=article, longId=122976, objectId=1b1f1229e69f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b1f1229e69f, replyNumber=0, likeNumber=27, createdTime=2018-04-02, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b1f1229e69f, moduleTitle=【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b1f1229e69f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652811, encodeId=b6a0165281109, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, objectType=article, longId=124749, objectId=622e124e49ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=622e124e49ed, replyNumber=0, likeNumber=68, createdTime=2018-04-28, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=622e124e49ed, moduleTitle=EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=622e124e49ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652815, encodeId=5743165281544, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, objectType=article, longId=125219, objectId=0ec912521937, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec912521937, replyNumber=0, likeNumber=0, createdTime=2018-08-05, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec912521937, moduleTitle=EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ec912521937)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652825, encodeId=a1411652825af, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Vertex在III期临床试验中测试CF三联疗法, objectType=article, longId=136761, objectId=2419136e61db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2419136e61db, replyNumber=0, likeNumber=55, createdTime=2018-10-16, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2419136e61db, moduleTitle=Vertex在III期临床试验中测试CF三联疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2419136e61db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652813, encodeId=dd60165281386, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验, objectType=article, longId=124996, objectId=11e112499612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11e112499612, replyNumber=0, likeNumber=58, createdTime=2018-11-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11e112499612, moduleTitle=EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11e112499612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652810, encodeId=e731165281010, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J Cancer：用以晚期实体瘤患者治疗的选择性MET酪氨酸激酶抑制剂SAR125844的I期临床, objectType=article, longId=124748, objectId=f1cf124e4855, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1cf124e4855, replyNumber=0, likeNumber=69, createdTime=2018-12-01, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1cf124e4855, moduleTitle=EUR J Cancer：用以晚期实体瘤患者治疗的选择性MET酪氨酸激酶抑制剂SAR125844的I期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1cf124e4855)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652833, encodeId=47ad16528332c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验, objectType=article, longId=146129, objectId=b5731461296f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5731461296f, replyNumber=0, likeNumber=50, createdTime=2018-09-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5731461296f, moduleTitle=HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5731461296f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652831, encodeId=848a16528311c, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=II期临床数据显示Ridinilazole治疗CDI时不影响肠道微生物组, objectType=article, longId=145963, objectId=4cb0145963c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cb0145963c1, replyNumber=0, likeNumber=61, createdTime=2019-01-15, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cb0145963c1, moduleTitle=II期临床数据显示Ridinilazole治疗CDI时不影响肠道微生物组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cb0145963c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652829, encodeId=d8661652829df, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, objectType=article, longId=142862, objectId=f2bb142862d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2bb142862d6, replyNumber=0, likeNumber=107, createdTime=2019-01-08, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2bb142862d6, moduleTitle=J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2bb142862d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652808, encodeId=89da165280862, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, objectType=article, longId=124108, objectId=397812410839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397812410839, replyNumber=0, likeNumber=58, createdTime=2018-05-22, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397812410839, moduleTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397812410839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652826, encodeId=6c721652826fa, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=曲马多治疗术后疼痛的III期临床数据, objectType=article, longId=138881, objectId=706b138881e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=706b138881e9, replyNumber=0, likeNumber=77, createdTime=2018-11-02, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=706b138881e9, moduleTitle=曲马多治疗术后疼痛的III期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=706b138881e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652795, encodeId=70751652e95a5, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究, objectType=article, longId=107571, objectId=185210e571e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=185210e571e9, replyNumber=0, likeNumber=68, createdTime=2017-12-26, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=185210e571e9, moduleTitle=Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=185210e571e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1652816, encodeId=d5ce1652816ec, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, objectTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, objectType=article, longId=125930, objectId=85ca1259307a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ca1259307a, replyNumber=0, likeNumber=61, createdTime=2018-11-30, rootId=0, userName=医生2402, userId=fc1f24335670, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ca1259307a, moduleTitle=Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85ca1259307a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

I期临床

2020-05-29

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

AsiDNA 治疗晚期实体瘤的I期临床试验正式启动

2018-12-07

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Theravance生物制药宣布TD-8236进入I期临床试验

2019-06-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

柳叶刀公布了Kyowa Kirin公司CCR4单抗Poteligeo 治疗皮肤T细胞淋巴瘤的III期临床数据

2019-03-31

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

【2017 ASH】Icll-07 Filo II期临床研究结果：伊布替尼+奥法木单抗联合免疫化疗以实现未经治疗的慢性淋巴细胞白血病患者微小病变残留阴性

2018-05-04

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Clin Oncol：II期临床显示Crizotinib在东亚患者中具有抗肿瘤活性

2018-09-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

III期临床TOLEDO研究显示阿扑吗啡可有效缓解帕金森病（PD）患者的持续运动波动

2019-03-20

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

每月注射一次的长效HIV疗法cabotegravir/rilpivirine III期临床实验喜获成功

2018-10-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

【2017 ASH】II期临床结果表明伊布替尼联合Venetoclax 对复发难治性以及遗传高风险CLL患者效果显著

2018-04-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EUR J Cancer：veliparib治疗BRCA突变的胰腺导管腺癌的II期临床试验

2018-04-28

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EUR J Cancer：聚乙二醇化脂质体多柔比星联合trebananib或安慰剂治疗卵巢癌的随机双盲III期临床试验

2018-08-05

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Vertex在III期临床试验中测试CF三联疗法

2018-10-16

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EUR J Cancer：舒尼替尼治疗局部晚期或转移性、间变性甲状腺髓质癌的多中心II期临床试验

2018-11-30

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EUR J Cancer：用以晚期实体瘤患者治疗的选择性MET酪氨酸激酶抑制剂SAR125844的I期临床

2018-12-01

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

HPN424治疗转移性去势抵抗性前列腺癌（mCRPC）的I期临床试验

2018-09-22

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

II期临床数据显示Ridinilazole治疗CDI时不影响肠道微生物组

2019-01-15

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

J Rheumatol：托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况：III期临床试验数据

2019-01-08

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验

2018-05-22

一叶知秋 (审核中...)

前往app查看评论内容

#I期临床#

曲马多治疗术后疼痛的III期临床数据

2018-11-02

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet Neurol：替奈普酶vs阿替普酶——NOR-TESTIII期临床研究

2017-12-26

医生2402 (审核中...)

前往app查看评论内容

#I期临床#

Lancet：度鲁特韦联合利匹韦林治疗HIV-1型III期临床研究

2018-11-30

科室
- - 订阅+
  - 更多科室
工具
服务